SCHEMBL10133649

SCHEMBL10133649

O=C1NCc2cc(-c3ccc(Nc4ccc(S(=O)(=O)N5CCOCC5)nc4)c4nccn34)ccc21

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 9/20 0.58
AURKA O14965 1/20 0.41
AURKB Q96GD4 1/20 0.41
TBK1 Q9UHD2 1/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
MTOR P42345 1/20 0.38
PIK3CG P48736 1/20 0.38
MAP4K1 Q92918 2/20 0.35
PFKFB3 Q16875 1/20 0.35
MAPK10 P53779 1/20 0.34
GSK3B P49841 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TGFBR1 P36897 1/20 0.34
ACVR1 Q04771 1/20 0.34
FYN P06241 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14162676 0.91 MAPKAPK5 (0.57) MAPKAPK5AURKAAURKBTBK1PIK3CD
SCHEMBL1685135 0.90 MAPKAPK5 (0.60) MAPKAPK5AURKAAURKBTBK1PIK3CD
SCHEMBL12424132 0.87 MAPKAPK5 (0.59) MAPKAPK5TBK1PIK3CDPIK3CAPIK3CB
SCHEMBL10133600 0.86 MAPKAPK5 (0.55) MAPKAPK5AURKAAURKBPIK3CAALDH1A1
SCHEMBL1685130 0.84 MAPKAPK5 (0.77) MAPKAPK5TBK1PIK3CDPIK3CAPIK3CB
SCHEMBL14162483 0.83 MAPKAPK5 (0.58) MAPKAPK5TBK1PIK3CDPIK3CAPIK3CB
SCHEMBL10133653 0.83 MAPKAPK5 (0.49) MAPKAPK5TBK1MAP4K1GSK3BTGFBR1
SCHEMBL10133651 0.82 MAPKAPK5 (0.51) MAPKAPK5AURKAAURKBMAP4K1ALDH1A1
SCHEMBL14162498 0.81 MAPKAPK5 (0.57) MAPKAPK5TBK1PIK3CDPIK3CAPIK3CB
SCHEMBL1685207 0.80 MAPKAPK5 (0.60) MAPKAPK5TBK1PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
WO-2008065199-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885AURKA 3833/4885AURKB 3410/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885AURKA 3833/4885AURKB 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.